spacer
home > epc > autumn 2002 > clinical trials in bulgaria
PUBLICATIONS
European Pharmaceutical Contractor

Clinical Trials in Bulgaria

Site Selection and Investigator Identification

Highly critical to the success of any study, these two issues require the utmost care. The decision-making process regarding both site and investigator should make full use of all local expertise:
Local opinion leaders will be well acquainted with the available professionals in the
area, as well as with its hospital structure and facilities
Local CROs and pharmaceutical companies' affiliate offices (affiliates) will have
hands-on experience of potential investigators and sites

This expertise should provide valuable information regarding site potential and suitability for trial requirements, for example available beds, medical/lab equipment, clinical supply, storage facilities and so on. They can also be helpful for assessing a site's desirability, for instance location, physical layout, access to IRB/IEC, quality of clinical trial teams and a suitable patient pool. Utilising these resources, whilst fundamental, is not without potential problems.

For example one should always be aware of the risk of commercial interests affecting advice given by affiliates during site/investigator selection. In an emerging scientific market commercial potential is limited, and therefore sales and marketing opportunities should be carefully balanced with clinical development. In our opinion, the emphasis should be put on clinical development performance. It is much more important to assess a site's real suitability and an investigator's capabilities in new drug trial implementation, rather than future marketing potential.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
In our Summer 2002 issue, Dr Milen Vrabevski, Medical Director at Comac Medical, began an in-depth overview of clinical trials in his native Bulgaria. Here he continues his investigation of the advantages and potential pitfalls for multinational pharmaceuticals operating in emerging scientific markets.

Dr Milen Vrabevski is Medical Director of Comac Medical Ltd., a full service small CRO based in Sofia, Bulgaria. He has over five years of experience in the pharmaceutical industry, mainly in the field of clinical research.

After graduating from the Medical University of Varna in 1995, Milen began his career working as a Junior Doctor in a surgery department, and then as a Medical Representative of a pharmaceutical company before founding Comac Medical Ltd. in 1997, assuming the position of Director.

Being one of the pioneers in the GCP and Quality of Life (QoL) area in his country, Milen has participated in conducting all company clinical studies and QoL projects.

spacer
Dr Milen Vrabevski
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IATA CEIV Pharma certificate of Turkish Cargo renewed

Turkish Cargo, the air cargo brand flying to the most countries around the world, extended the validity period of its IATA CEIV (Center of Excellence for Independent Validators) Pharma certificate to 2022, proving its success in all processes throughout the air transportation of medicinal products.
More info >>

White Papers

Clinical Trial-Specific Travel Programs as a Patient Retention Tool

For many patients, participating in a clinical trial is a major endeavor. Depending on the protocol requirements, study visits can be exhausting. There are a number of reasons why a patient may choose to participate in a trial only to drop out. Conversely, there are several approaches to proactively try to prevent this from happening. There are various methods professionals implement for patient retention. This white paper explores patient travel services as one patient retention strategy.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India forhigh quality, low   cost pharma solutions, CPhI & P-MEC Indiais the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India’s pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement